AI assistant
Roivant Sciences Ltd. — Director's Dealing 2025
Feb 19, 2025
30587_dirs_2025-02-18_5cd651dd-6351-4a74-9374-96f7e31f972b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2025-02-13
Reporting Person: Kumar Rakhi (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-13 | Common Shares | M | 187500 | $3.85 | Acquired | 390764 | Direct |
| 2025-02-13 | Common Shares | S | 227500 | $10.43 | Disposed | 163264 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-13 | Stock Option (Right to Buy) | $3.85 | M | 187500 | Disposed | 2032-04-19 | Common Stock (187500) | Direct |
Footnotes
F1: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).